Lead Sponsor

QLT Inc.

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

•Treatment naive for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye except for laser treatment outside the subfoveal area
•Subfoveal CNV due to AMD
•CNV must be = or \>50 % of the entire lesion
•All lesion composition types with a lesion greatest linear dimension (GLD) \< 5400 microns (approximately = or \<9 disc areas \[DA\])
•Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA score) of 25 - 73 letters (approximate Snellen equivalent of 20/40 - 20/320), inclusive

•Subfoveal geographic atrophy or subfoveal fibrosis of the study eye
•Intraocular surgery within 3 months of enrollment
•Inability to attend the protocol-required visits
•Known allergies or hypersensitivity to any of the study treatments.
•Other systemic diseases or active uncontrolled infections that would make subject a poor medical risk
•Uncontrolled glaucoma, defined as (1)subject is on \>1 glaucoma medication (includes combination treatments) or (2)subject has glaucoma that could lead to progressive visual field deterioration
•If subject has had a stroke within the last year

Related studies

NCT05803785 · Age-Related Macular Degeneration

NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07550777 · Diabete Mellitus, Retina Vein Occlusion, and more

NCT07440225 · Macular Degeneration, Age-Related Macular Degeneration, and more

NCT05407636 · AMD, nAMD, and more

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)